Study protocol: Randomized, open-label, non-inferiority clinical trial for evaluating the clinical and pathological response rates to neoadjuvant hormone therapy and chemotherapy in patients with luminal-subtype breast tumors

BACKGROUND: Despite neoadjuvant hormone therapy (NHT) is being underused, it is an effective treatment for luminal tumors at a lower cost and with fewer side effects compared to those associated with neoadjuvant chemotherapy (NCT). The lack of robust comparative data between NHT and NCT is a factor...

Descripción completa

Detalles Bibliográficos
Autores principales: Gouveia, Maria Carolina, Amorim de Araújo Lima Santos, Candice, Impieri Souza, Ariani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574413/
https://www.ncbi.nlm.nih.gov/pubmed/36262803
http://dx.doi.org/10.1016/j.conctc.2022.101013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574413/
https://www.ncbi.nlm.nih.gov/pubmed/36262803
http://dx.doi.org/10.1016/j.conctc.2022.101013

Ejemplares similares